Altered expression of mitochondrial and extracellular matrix genes in the heart of human fetuses with chromosome 21 trisomy

BackgroundThe Down syndrome phenotype has been attributed to overexpression of chromosome 21 (Hsa21) genes. However, the expression profile of Hsa21 genes in trisomic human subjects as well as their effects on genes located on different chromosomes are largely unknown. Using oligonucleotide microarrays we compared the gene expression profiles of hearts of human fetuses with and without Hsa21 trisomy.ResultsApproximately half of the 15,000 genes examined (87 of the 168 genes on Hsa21) were expressed in the heart at 18–22 weeks of gestation. Hsa21 gene expression was globally upregulated 1.5 fold in trisomic samples. However, not all genes were equally dysregulated and 25 genes were not upregulated at all. Genes located on other chromosomes were also significantly dysregulated. Functional class scoring and gene set enrichment analyses of 473 genes, differentially expressed between trisomic and non-trisomic hearts, revealed downregulation of genes encoding mitochondrial enzymes and upregulation of genes encoding extracellular matrix proteins. There were no significant differences between trisomic fetuses with and without heart defects.ConclusionWe conclude that dosage-dependent upregulation of Hsa21 genes causes dysregulation of the genes responsible for mitochondrial function and for the extracellular matrix organization in the fetal heart of trisomic subjects. These alterations might be harbingers of the heart defects associated with Hsa21 trisomy, which could be based on elusive mechanisms involving genetic variability, environmental factors and/or stochastic events.

[1]  Tak W. Mak,et al.  Role of the NF-ATc transcription factor in morphogenesis of cardiac valves and septum , 1998, Nature.

[2]  Xin Gao,et al.  NFAT dysregulation by increased dosage of DSCR1 and DYRK1A on chromosome 21 , 2006, Nature.

[3]  E. Zackai,et al.  Down syndrome congenital heart disease: A narrowed region and a candidate gene , 2001, Genetics in Medicine.

[4]  Alexandre Reymond,et al.  Evolutionary Discrimination of Mammalian Conserved Non-Genic Sequences (CNGs) , 2003, Science.

[5]  M. Destrempes,et al.  Increased adhesiveness of Down syndrome fetal fibroblasts in vitro. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[6]  C. Disteche,et al.  Down syndrome phenotypes: the consequences of chromosomal imbalance. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[7]  Bing Zhang,et al.  GOTree Machine (GOTM): a web-based platform for interpreting sets of interesting genes using Gene Ontology hierarchies , 2004, BMC Bioinformatics.

[8]  K. Yamakawa,et al.  Mitochondrial dysfunction and tau hyperphosphorylation in Ts1Cje, a mouse model for Down syndrome. , 2006, Human molecular genetics.

[9]  T. Pawson,et al.  The discoidin domain receptor tyrosine kinases are activated by collagen. , 1997, Molecular cell.

[10]  C. Epstein.  The Consequences of Chromosome Imbalance: Gene dosage effects , 1986 .

[11]  K. Gardiner.  Gene-dosage effects in Down syndrome and trisomic mouse models , 2004, Genome Biology.

[12]  Zhijin Wu,et al.  Preprocessing of oligonucleotide array data , 2004, Nature Biotechnology.

[13]  K. Yutzey,et al.  NFATc 3 and NFATc 4 Are Required for Cardiac Development and Mitochondrial Function , 2003 .

[14]  A. Bosio,et al.  An extracellular matrix-specific microarray allowed the identification of target genes downstream of discoidin domain receptors. , 2003, Matrix biology : journal of the International Society for Matrix Biology.

[15]  David W. Mount,et al.  Pathway Miner: extracting gene association networks from molecular pathways for predicting the biological significance of gene expression microarray data , 2004, Bioinform..

[16]  B. Rothermel,et al.  Restoration of DSCR1 to disomy in the trisomy 16 mouse model of Down syndrome does not correct cardiac or craniofacial development anomalies , 2005, Developmental dynamics : an official publication of the American Association of Anatomists.

[17]  M. Eisen,et al.  Gene expression informatics —it's all in your mine , 1999, Nature Genetics.

[18]  L. W. Perry,et al.  Congenital cardiovascular malformations associated with chromosome abnormalities: an epidemiologic study. , 1989, The Journal of pediatrics.

[19]  H. Cuckle,et al.  Mitochondrial dysfunction and Down's syndrome. , 2002, BioEssays : news and reviews in molecular, cellular and developmental biology.

[20]  A. G. Gittenberger-de Groot,et al.  Collagen type VI expression during cardiac development and in human fetuses with trisomy 21. , 2003, The anatomical record. Part A, Discoveries in molecular, cellular, and evolutionary biology.

[21]  L. Vitale,et al.  Gene Expression Profile Analysis in Human T Lymphocytes from Patients with Down Syndrome , 2004, Annals of human genetics.

[22]  M. Yaspo,et al.  Protein levels of genes encoded on chromosome 21 in fetal Down syndrome brain: Challenging the gene dosage effect hypothesis (Part I) , 2003, Amino Acids.

[23]  E. Courchesne,et al.  Protocols to establish genotype-phenotype correlations in Down syndrome. , 1991, American journal of human genetics.

[24]  I. Kola,et al.  Tissue-specific overexpression of the HSA21 gene GABPalpha: implications for DS. , 2004, Biochimica et biophysica acta.

[25]  T. Speed,et al.  Summaries of Affymetrix GeneChip probe level data. , 2003, Nucleic acids research.

[26]  K. Yamakawa,et al.  Dosage-dependent over-expression of genes in the trisomic region of Ts1Cje mouse model for Down syndrome. , 2004, Human molecular genetics.

[27]  R. Price,et al.  Expression of Discoidin Domain Receptor 2 (DDR2) in the Developing Heart , 2005, Microscopy and Microanalysis.

[28]  Bin Yu,et al.  Simultaneous Gene Clustering and Subset Selection for Sample Classification Via MDL , 2003, Bioinform..

[29]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[30]  J. Quigley,et al.  MMP‐2 expression during early avian cardiac and neural crest morphogenesis , 2000, The Anatomical record.

[31]  W. Engel,et al.  Transfer of beta-amyloid precursor protein gene using adenovirus vector causes mitochondrial abnormalities in cultured normal human muscle. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[32]  I. Graef,et al.  NFAT signaling in vertebrate development. , 2001, Current opinion in genetics & development.

[33]  J. Prince,et al.  Mitochondrial enzyme deficiencies in Down's syndrome , 1994, Journal of neural transmission. Parkinson's disease and dementia section.

[34]  N. Cairns,et al.  Decreased levels of complex III core protein 1 and complex V β chain in brains from patients with Alzheimer’s disease and Down syndrome , 2000, Cellular and Molecular Life Sciences CMLS.

[35]  X. Estivill,et al.  DSCR1, overexpressed in Down syndrome, is an inhibitor of calcineurin-mediated signaling pathways. , 2000, Human molecular genetics.

[36]  C. Markert,et al.  Developmental genetics , 2005, Experientia.

[37]  J. Delabar,et al.  Molecular Mapping of Twenty-Four Features of Down Syndrome on Chromosome 21 , 1993, European journal of human genetics : EJHG.

[38]  S. South,et al.  Transcript level alterations reflect gene dosage effects across multiple tissues in a mouse model of down syndrome. , 2004, Genome research.

[39]  J. Wegiel,et al.  Trisomy-driven overexpression of DYRK1A kinase in the brain of subjects with Down syndrome , 2007, Neuroscience Letters.

[40]  H. Dvorak,et al.  Down Syndrome Candidate Region 1 Isoform 1 Mediates Angiogenesis through the Calcineurin-NFAT Pathway , 2006, Molecular Cancer Research.

[41]  S. Antonarakis,et al.  Gene expression from the aneuploid chromosome in a trisomy mouse model of down syndrome. , 2004, Genome research.

[42]  N. Cairns,et al.  The reduction of NADH ubiquinone oxidoreductase 24- and 75-kDa subunits in brains of patients with Down syndrome and Alzheimer's disease. , 2001, Life sciences.

[43]  S Matthysse,et al.  Increased adhesiveness of trisomy 21 cells and atrioventricular canal malformations in Down syndrome: a stochastic model. , 1985, American journal of medical genetics.

[44]  Raymond B. Runyan,et al.  Cell biology of cardiac cushion development. , 2005, International review of cytology.

[45]  J. McPherson,et al.  A Chromosome 21 Critical Region Does Not Cause Specific Down Syndrome Phenotypes , 2022 .

[46]  M. Moorhouse,et al.  DNA microarray analysis for human congenital heart disease , 2006, Cell Biochemistry and Biophysics.

[47]  A. Aurias,et al.  Critical role of the D21S55 region on chromosome 21 in the pathogenesis of Down syndrome. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[48]  K. Gardiner.  Predicting pathway perturbations in Down syndrome. , 2003, Journal of neural transmission. Supplementum.

[49]  J. Goodship,et al.  Developmental genetics of the heart. , 1996, Current opinion in genetics & development.

[50]  T. Pawson,et al.  Discoidin Domain Receptor 1 Tyrosine Kinase Has an Essential Role in Mammary Gland Development , 2001, Molecular and Cellular Biology.

[51]  M. Pletnikov,et al.  Trisomy for the Down syndrome 'critical region' is necessary but not sufficient for brain phenotypes of trisomic mice. , 2007, Human molecular genetics.

[52]  L. Personnaz,et al.  The cerebellar transcriptome during postnatal development of the Ts1Cje mouse, a segmental trisomy model for Down syndrome. , 2005, Human molecular genetics.

[53]  N. Hastie,et al.  Transcriptome analysis of human autosomal trisomy. , 2002, Human molecular genetics.

[54]  M. K. McCormick.  Molecular genetic approach to the characterization of the ‘Down syndrome region’ of chromosome 21 , 1989 .

[55]  G. Lubec,et al.  Evidence against the current hypothesis of "gene dosage effects" of trisomy 21: ets-2, encoded on chromosome 21" is not overexpressed in hearts of patients with Down Syndrome. , 1999, Biochemical and biophysical research communications.

[56]  N. Roizen,et al.  Down's syndrome , 2003, The Lancet.

[57]  J. Richtsmeier,et al.  Too much of a good thing: mechanisms of gene action in Down syndrome. , 2001, Trends in genetics : TIG.

[58]  Caine W. Wong,et al.  Altered Metabolism of the Amyloid β Precursor Protein Is Associated with Mitochondrial Dysfunction in Down's Syndrome , 2002, Neuron.

[59]  R. Reeves,et al.  Global disruption of the cerebellar transcriptome in a Down syndrome mouse model. , 2003, Human molecular genetics.

[60]  J. Aldridge,et al.  Genetics of Congenital Heart Malformations: A Stochastic Model a , 1985, Annals of the New York Academy of Sciences.

[61]  Burton L. Shapiro,et al.  Whither Down syndrome critical regions? , 1997, Human Genetics.

[62]  R. Rowe,et al.  Down syndrome with congenital heart malformation. , 1977, American journal of diseases of children.

[63]  Jonathan Pevsner,et al.  Global up-regulation of chromosome 21 gene expression in the developing Down syndrome brain. , 2003, Genomics.

[64]  I. Kola,et al.  Tissue-specific overexpression of the HSA21 gene GABPα: implications for DS , 2004 .

[65]  Ingo Ruczinski,et al.  Primary and secondary transcriptional effects in the developing human Down syndrome brain and heart , 2005, Genome Biology.

[66]  Katherine E Yutzey,et al.  NFATc3 and NFATc4 Are Required for Cardiac Development and Mitochondrial Function , 2003, Circulation research.

[67]  D. J. Driscoll,et al.  Molecular genetic approach to the characterization of the "Down syndrome region" of chromosome 21. , 1989, Genomics.